The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Lummicar-2: CT053 for R/R multiple myeloma
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the results of the Phase Ib/II Lummicar-2 study (NCT03915184) evaluating the safety and efficacy of the fully human B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy, CT053, in patients with relapsed/refractory (R/R) multiple myeloma. CT053 showed deep and rapid responses in patients, where a 100% overall response rate (ORR) was observed. Of 10 subjects, 4 achieved complete responses (CR) and 6 achieved partial responses (PR) after 4.5 months. Of 12 subjects with evaluable bone marrow, 11 were measurable residual disease (MRD)-negative. The therapy was well tolerated, with grade 1/2 cytokine release syndrome (CRS) the most common adverse event. Additionally, neurotoxicity was observed among 3 subjects within the first 3-4 days of therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
